Efficacy of PD-1/PD-L1 inhibitors in patients with advanced gastroesophageal cancer: An updated meta-analysis based on randomized controlled trials

Lihu Gu1,2,3†, Tongmin Huang4†, Shinan Qiu5, Jiaze Hong4, Rongrong Fu6, Chaoxiong Ni7, Senjie Dai4, Ping Chen1,2,3 and Ning He8*

1Department of General Surgery, Ningbo No. 2 Hospital, Ningbo, Zhejiang, China, 2Ningbo Institute of Life and Health Industry, University of Chinese Academy of Sciences, Ningbo, China, 3Key Laboratory of Diagnosis and Treatment of Digestive System Tumors of Zhejiang Province, Ningbo No. 2 Hospital, Ningbo, China, 4The Second Clinical Medical College, Zhejiang Chinese Medical University, Hangzhou, Zhejiang, China, 5Medical School of Ningbo University, Ningbo, Zhejiang, China, 6The First Clinical Medical College, Zhejiang Chinese Medical University, Hangzhou, Zhejiang, China, 7Department of Nephrology, QingChun Hospital of Zhejiang Province, Hangzhou, Zhejiang, China, 8Department of Tumor High-Intensity Focused Ultrasound (HIFU) Therapy, Ningbo No. 2 Hospital, Ningbo, Zhejiang, China

Background: This study aimed to investigate the clinical efficacy of programmed death-1 receptor and ligand-1 (PD-1/PD-L1) inhibitors in gastroesophageal cancer patients and the relationship between their clinicopathological features and curative treatment effects.

Methods: A systematic search was conducted for articles published before April 2022 from online databases (PubMed, EMBASE, Web of Science and the Cochrane Library). The main outcome was overall survival (OS).

Results: This meta-analysis comprised 16 studies involving 9,304 participants. The results indicated that compared with chemotherapy, patients treated with PD-1/PD-L1 inhibitors had significantly improved OS (HR = 0.80; \( p < 0.001 \)) but no significant improvement in progression-free survival (PFS) (\( p = 0.185 \)). Subgroup analyses demonstrated that PD-1/PD-L1 inhibitors combined with chemotherapy, esophageal squamous cell carcinoma, male, Asian patients and combined positive score (CPS) \( \geq 1 \) were significantly associated with better survival outcomes. Further, subgroup analysis of gender revealed that the OS of all subgroups containing male patients was significantly improved compared with those not containing male patients.

Abbreviations: 1L, first line; 2L, second line; 3L, third line; BSC, best supportive care; CI, confidence interval; CPS, PD-L1 combined positive score; E, esophageal cancer; ECOG, eastern cooperative oncology group; FDA, the Food and Drug Administration; G, gastric cancer; GEJ, gastroesophageal junction cancer; H. pylori, Helicobacter pylori; HR, hazard ratio; ICIs, immune checkpoint inhibitors; IL, interleukin; MHC, major histocompatibility complex; MSI-H, microsatellite instability-high; NA, no available; OS, overall survival; PD-1, programmed death-1 receptor; PD-L1, programmed death ligand-1; PFS, progression-free survival; RCTs, randomized controlled trials; RE, random-effects; TCGA, the Japanese Endoscopy society and The Cancer Genomic Atlas; TMB, tumor mutation burden; TPS, PD-L1 tumour proportion score.
with chemotherapy, unlike that of female patients. In addition, the line of therapy, Lauren classification, age and eastern cooperative oncology group (ECOG) performance status were not associated with PD-1/PD-L1 inhibitors efficacy.

**Conclusion:** The results indicated that PD-1/PD-L1 inhibitors could prolong the OS of advanced gastroesophageal cancer patients. Clinicopathological features such as therapeutic schedules, tumor types, histological type, gender, geographical region and PD-L1 expression status (CPS) seemed to be associated with survival outcomes.

**KEYWORDS**
PD-1/PD-L1 inhibitors, gastroesophageal cancer, survival, clinicopathological features, sex, meta-analysis

**Introduction**

Gastroesophageal cancer, one of the most lethal malignant tumors with a dismal prognosis, can be anatomically separated into esophageal cancer, gastroesophageal junction cancer and gastric cancer. As per the GLOBOCAN 2020 assessment of cancer incidence and mortality (Sung et al., 2021), it is estimated that there will be approximately more than 540,000 cases of esophageal cancer and 760,000 cases of gastric cancer deaths each year, making esophageal cancer and gastric cancer the sixth and third causes of cancer mortality globally. Due to the indolent course of the disease in its early stage, most gastroesophageal cancer patients have already reached advanced stages by the time of diagnosis and thereby have dismal prognoses (Ajani et al., 2016; Van Cutsem et al., 2016). Consequently, single or combination therapy with chemotherapy, targeted therapy and radiotherapy are the main methods to enhance the survival and quality of life of the patients. Currently, the first-line treatment for advanced gastroesophageal cancer consists of 5-FU/platinum-based chemotherapy and targeted therapy. Nonetheless, chemotherapy, targeted therapy, and radiotherapy have been reported to have limited efficacy, with 5-years survival rates ranging from 15% to 25% (Zou et al., 2016; Bray et al., 2018).

Recently, immune checkpoint inhibitors (ICIs), particularly programmed death-1 receptor and ligand-1 (PD-1/PD-L1) inhibitors, have shown promising prospects in prolonging the survival of advanced cancer. By blocking related immune checkpoint signaling pathways, ICIs can restore the anti-tumor immune responses of immune cells (Sharma and Allison, 2015). The Food and Drug Administration (FDA) has approved the use of numerous PD-1/PD-L1 inhibitors for the clinical treatment of some cancers (Ni et al., 2020). For instance, pembrolizumab in combination with trastuzumab and chemotherapy for first-line treatment of metastatic HER-2 positive gastric cancer, and nivolumab combined with chemotherapy in the first-line setting for the treatment of advanced gastroesophageal cancer (Weadick et al., 2022). However, since the response rates to PD-1/PD-L1 inhibitors remain unsatisfactory in most patients, this has restricted their clinical applications (Yi et al., 2018). Some scholars have turned their attention to exploring markers that could effectively predict the efficacy of PD-1/PD-L1 inhibitors, with the hope of screening latent patients who would effectively respond to PD-1/PD-L1 inhibitors before treatment; thus, improving their treatment outcomes.

Previously, subgroup analyses of markers affecting the efficacy of PD-1/PD-L1 inhibitors in gastroesophageal cancer were performed through two meta-analyses (Formica et al., 2021; Oh et al., 2021), but given the limited number of studies included, inconsistency of research design and significant heterogeneity among the included studies, the credibility of their results and conclusions seemed limited. Hence, based on the latest evidence from randomized controlled trials (RCTs), an updated meta-analysis will be executed to probe the clinical efficacy of PD-1/PD-L1 inhibitors in advanced gastroesophageal cancer and the association between patients’ clinicopathological features (therapeutic schedules, sex, age, etc.) and curative treatment effects depression.

**Methods**

This meta-analysis was carried out in accordance with the preferred reporting items for Systematic Review and Meta-Analysis (PRISMA) 2015 (Moher et al., 2015), and the prospective protocol was registered on the PROSPERO (CRD42022327617).

**Search strategy**

Two authors separately conducted a systematic search of PubMed, EMBASE, Web of Science and the Cochrane Library to identify all potentially RCTs relevant to the efficacy of PD-1/PD-L1 inhibitors in esophageal cancer, gastroesophageal junction cancer and gastric cancer. And the scope of the literature search was restricted to the time span from inception of the databases to
April 2022. Random combinations of free-text terms and medical subject headings terms were used to retrieve literature. And search terms included “PD-1” OR “PD-L1” OR “programmed death 1” OR “programmed death ligand 1” OR “nivolumab” OR “BMS 936558” OR “BMS 93659” OR “MDX 1105” OR “pembrolizumab” OR “lambrolizumab” OR “MK 3475” OR “pidilizumab” OR “CT 011” OR “durvalumab” OR “MEDI 4736” OR “atezolizumab” OR “MPDL 3280a” OR “avelumab” OR “AMP 224” OR “toripalimab” OR “camrelizumab” OR “SHR-1210” OR “sintilimab” OR “tislelizumab” OR “penpulimab” OR “zimberelimab” OR “envafolinimab” OR “cemiplimab” AND “stomach neoplasms” OR “esophageal neoplasms” OR “gastric cancer” OR “esophageal cancer” OR “gastro-oesophageal junction cancer”. To avoid omission of any latently relevant research, the references to the primary articles and pertinent reviews were manually examined as well.

Inclusion and exclusion criteria

The inclusion criteria were as follows: (Sung et al., 2021) RCTs were included in the study; (Ajani et al., 2016) patients suffering from either advanced esophageal, gastroesophageal junction or gastric cancer; (Van Cutsem et al., 2016) studies in which patients in the intervention group received PD-1/PD-L1 checkpoint inhibitors as a monotherapy or combined with other therapies (immunotherapy, chemotherapy, targeted therapy, and radiotherapy), while patients in the control group received placebo or other therapies that did not include PD-1/PD-L1 inhibitors; (Bray et al., 2018) study in which efficacy data of overall survival (OS), progression-free survival (PFS) was available.

The exclusion criteria were as follows: (Sung et al., 2021) articles not published in English; (Ajani et al., 2016) studies that fell within the category of adjuvant therapy or neoadjuvant therapy; (Van Cutsem et al., 2016) articles that were duplicated (the latest published or most complete article would be chosen for inclusion); (Bray et al., 2018) articles that were study protocols or did not report any relevant outcomes; (Zou et al., 2016) articles in which unable to access the full text or extract available data were not available.

Data extraction

Data from each study were extracted by two investigators independently in the light of a pre-designed data extraction table. And any discrepancies were ironed out through third-party arbitration. The following information was extracted: Author, year of publication, country, trial phase, therapy lines, tumour type, sample size, therapeutic schedule, median follow up duration, participants’ characteristics (e.g., mean age, sex ratio, eastern cooperative oncology group (ECOG) performance status, geographic region), trial registration number, and data on survival outcomes. Furthermore, the data were also collected for the pre-defined subgroups listed below: therapy lines, therapeutic schedules, tumour types, age, ECOG performance status, sex, geographical region, PD-L1 expression status.

Quality evaluation and outcome measures

The Cochrane Collaborative Risk of Bias Assessment Tool was employed to appraise the potential risk of bias in RCTs (Higgins et al., 2011), which contained seven domains: random sequence generation, allocation concealment, blinding of participants and personnel, blinding of outcome assessment, incomplete outcome data, selective reporting and other source of bias. And the risk was divided into three levels: high risk, unclear risk, and low risk. The results showed that all of the studies included in the analysis had acceptable quality.

The primary efficacy objective of this meta-analysis was to determine the impact of PD-1/PD-L1 inhibitors on OS and PFS in patients with advanced esophageal, gastroesophageal junction or gastric cancer, as evaluated by the interaction hazard ratio (HR).

Statistical analysis

By using Stata 12.0 software, the distinct data extracted in each included study were combined, so as to evaluate the efficacy of PD-1/PD-L1 inhibitors. The effect size was calculated as HR with 95% confidence interval (CI). For the total sample, the heterogeneity test was examined using the Cochran chi-squared and quantified using the inconsistency test (I2). According to the Cochrane Manual and study characteristics (Higgins et al., 2003), I2 values of 0%–30% showed mild or insignificant heterogeneity, 30%–70% revealed moderate heterogeneity, and 70%–100% indicated high or substantial heterogeneity. Considering the uncertainty of heterogeneity and the complexity of control conditions between included studies, a random-effects (RE) model was applied to meta-analysis. All probabilities (p values) of data were two-sided, with p < 0.05 considered as statistically significant.

To detect the latent variables leading to sources of heterogeneity, pre-specified subgroup analyses were executed. When included articles ≥10, the publication bias was assessed using Begg’s weighted regression test with significance set at p < 0.1 (Shen et al., 2019). Moreover, through excluding each study successively, the sensitivity analysis were performed as well.

Results

Study selection

A total of 75,194 related records were screened following the database search. After removal of 7,866 duplicate studies,
67,328 studies were ruled out since their title and abstract did not match the inclusion criteria. Next, after reviewing and evaluating the full text of the remaining 534 studies, 487 articles were removed as the result of non-RCT, 15 study protocols were ruled out, and 2 were excluded due to adjuvant or neoadjuvant therapy studies. Furthermore, six studies were eliminated because of duplicate reports, seven articles were excluded owing to the fact that they failed to report relevant outcomes. In virtue of data unavailable, one trial was also removed. Ultimately, 16 studies (Bang et al., 2018; Huang et al., 2020; Kojima et al., 2020; Shitara et al., 2020; Boku et al., 2021; Janjigian et al., 2021; Luo et al., 2021; Sun et al., 2021; Chung et al., 2022; Doki et al., 2022; Fuchs et al., 2022; Kang et al., 2022; Wang et al., 2022) were included in conformity to inclusion and exclusion criteria, the flow chart for the selection procedure and specific identification is manifested in Figure 1.

**Study characteristics and quality assessment**

The fundamental characteristics of 16 studies demonstrating the efficacy of PD-1/PD-L1 inhibitors in patients suffered from advanced esophageal, gastroesophageal junction or gastric cancers are shown in Table 1; Supplementary Table S1. These studies comprised a total of 9,304 patients, including 4,865 in the experimental group and 4,439 in the control group. Among them, 15 studies were in phase III except one in phase II. The tumor types were comprised of esophageal, gastroesophageal junction and gastric cancer. For therapeutic schedules, eight studies (Shitara et al., 2020; Boku et al., 2021; Janjigian et al., 2021; Luo et al., 2021; Sun et al., 2021; Doki et al., 2022; Kang et al., 2022; Wang et al., 2022) included PD-1/PD-L1 inhibitors combined with chemotherapy versus chemotherapy, nine studies (Bang et al., 2018; Huang et al., 2020; Kojima et al., 2020; Shitara et al., 2020; Moehler et al., 2021; Chung et al., 2022; Fuchs et al., 2022; Okada et al., 2022; Xu et al., 2022) contained PD-1/PD-L1 inhibitor monotherapy versus chemotherapy, while one study (Boku et al., 2021) involved PD-1/PD-L1 inhibitor monotherapy versus placebo [one study was a three-arm clinical trial, including the group of PD-1/PD-L1 inhibitors combined with chemotherapy, the group of PD-1/PD-L1 inhibitors monotherapy and chemotherapy group (Shitara et al., 2020)]. The median follow-up time varied from 4.1 to 17.45 weeks. The detailed quality assessments, based on the Cochrane Collaboration’s tool, of the 16 studies are shown in
Supplementary Figures S1, S2. Due to their open-label design, most of the trials had a high risk of performance bias. Other domains were assured with reasonably low risk based on the inclusion of high-quality RCTs. The overall quality was in accord with the meta-analysis criteria.

**Overall survival outcomes**

Pooled analysis of the 16 studies for OS showed that patients treated with PD-1/PD-L1 inhibitors had longer OS compared with controls (HR = 0.80; 95% CI: 0.75–0.86; I² = 51.1%; p < 0.001) (Figure 2), indicating that PD-1/PD-L1 inhibitors (monotherapy or combined with chemotherapy) could prolong the OS of esophageal, gastroesophageal junction and gastric cancer patients.

In subgroup analysis, when the line of therapy was divided into first-line therapy and non-first-line therapy, the results indicated that the OS of patients who received PD-1/PD-L1 inhibitors was significantly longer than controls in both first-line (HR = 0.80; p < 0.001) and non-first-line (HR = 0.81; p = 0.010) treatments. In regards to subgroup analyses of therapeutic schedules, patients in the PD-1/PD-L1 inhibitors group had a longer OS than controls, irrespective of whether they were treated with PD-1/PD-L1 inhibitors combined with chemotherapy (HR = 0.75; p < 0.001) or PD-1/PD-L1 inhibitor monotherapy (HR = 0.87; p = 0.003). However, the results also showed that the curative effect of PD-1/PD-

---

**TABLE 1** The characteristics of studies included in this meta-analysis.

| Author, year | Country | Phase | Line | Tumour | Sample size | Interventions | Median follow-up (weeks) |
|--------------|---------|-------|------|--------|-------------|---------------|------------------------|
| Boku, 2021   | USA     | III   | 2L, 3L | GEJ, G | 330, 163    | Nivolumab, Placebo | 5.3, 4.1               |
| Janjigian, 2021 | USA | III   | 1L | E, GEJ, G | 789, 792 | Nivolumab + Chemotherapy, Chemo | 13.8, 11.6             |
| Kang, 2022   | South Korea | III | 1L | GEJ, G | 362, 362 | Nivolumab + Chemotherapy, Placebo + Chemo | 17.45, 17.15           |
| Shitara, 2020 | Spain  | III   | 1L | GEJ, G | 257, 256, 250 | Pembrolizumab + Chemotherapy, Pembrolizumab | 12.5a, 11.1a, 10.8c, 10.6a, 17.4c |
| Sun, 2021    | South Korea | III | 1L | E, GEJ | 373, 376 | Pembrolizumab + Chemotherapy, Placebo + Chemo | 12.4, 9.8               |
| Doki, 2022   | Japan    | III   | 1L | E | 321, 324 | Nivolumab + Chemotherapy, Chemotherapy | 13.2, 10.7             |
| Wang, 2022   | China    | III   | 1L | E | 257, 257 | Toripalimab + Chemotherapy, Placebo + Chemo | 17, 11                  |
| Luo, 2021    | China    | III   | 1L | E | 298, 298 | Camrelizumab + Chemotherapy, Placebo + Chemo | 15.3, 12.0             |
| Chung, 2022  | South Korea | III | 1L | E, GEJ | 47, 47 | Pembrolizumab, Chemotherapy | 8, 8                   |
| Fuchs, 2022  | USA      | III   | 2L | GEJ, G | 294, 296 | Pembrolizumab, Chemotherapy | 9.1a, 10.4b,c, 8.3a,b, 10.8c |
| Bang, 2018   | South Korea | III | 3L | GEJ, G | 185, 186 | Avelumab + BSC, Chemotherapy + BSC | 4.6, 5.0               |
| Moehler, 2021 | Germany | III   | 1L | GEJ, G | 249, 250 | Avelumab, Chemotherapy + BSC | 10.4, 10.9             |
| Kojima, 2020 | Japan    | III   | 1L | E, GEJ | 314, 314 | Pembrolizumab, Chemotherapy | 7.1, 7.1               |
| Huang, 2020  | China    | III   | 2L | E | 228, 220 | Camrelizumab, Chemotherapy | 8.3, 6.2               |
| Okada, 2022  | Japan    | III   | 2L | E | 210, 209 | Nivolumab, Chemotherapy | 10.9, 8.5              |
| Xu, 2022     | China    | II    | 2L | E | 95, 95 | Sintilimab, Chemotherapy | 7.2, 6.2               |

1L, first line; 2L, second line; 3L, third line; E, esophageal cancer; GEJ, gastroesophageal junction cancer; G, gastric cancer; BSC, best supportive care; PD-L1, programmed death ligand-1; CPS, PD-L1 combined positive score.

*aMedian follow-up duration in patients with PD-L1 CPS ≥ 1.
*bMedian follow-up duration in patients with PD-L1 CPS ≥ 5.
*cMedian follow-up duration in patients with PD-L1 CPS ≥ 10.
L1 inhibitors combined with chemotherapy seemed to be better than that of PD-1/PD-L1 inhibitor monotherapy.

To investigate the effects of different tumor types on the efficacy of PD-1/PD-L1 inhibitors, relevant studies were categorized into esophageal cancer (HR = 0.75; \( p < 0.001 \)), gastroesophageal junction cancer (HR = 0.87; \( p = 0.040 \)) and gastric cancer (HR = 0.87; \( p = 0.019 \)) (Table 2). Pooled analysis showed that compared with the control group, the OS of patients treated with PD-1/PD-L1 inhibitors was improved in all three tumor types, with esophageal cancer benefiting more from PD-1/PD-L1 inhibitors (HR = 0.75; \( p < 0.001 \)). Among them, when the esophageal cancer cases were grouped into adenocarcinoma and squamous cell carcinoma subgroups based on histological classification, compared with the control group, patients with esophageal squamous cell carcinoma were found to have prolonged OS (HR = 0.75; \( p < 0.001 \)), while no statistical difference was discovered in patients with esophageal adenocarcinoma between the experimental group and the control group (\( p = 0.679 \)). In regard to gastric cancer, when the patients were classified into intestinal and diffuse types based on the Lauren classification, the results showed that PD-1/PD-L1 inhibitors could improve the OS of both intestinal (HR = 0.80; 95% CI: 0.71–0.92) and diffuse (HR = 0.84; 95% CI: 0.72–0.99) types compared with the control group. The pooled effects are as emerged in Table 2.

For age subgroup analysis, 65 years was used as the threshold. The analysis results demonstrated that compared with the control group, patients receiving PD-1/PD-L1 inhibitors benefited from longer OS in both <65 years (HR = 0.81; 95% CI: 0.75–0.87) and ≥65 years (HR = 0.80; 95% CI: 0.73–0.88) groups. For subgroup analysis on ECOG performance status 0 or 1, the results showed that compared with the control group, the OS of patients treated with PD-1/PD-L1 inhibitors was also prolonged in the ECOG performance status 0 (HR = 0.82; 95% CI: 0.73–0.91) and status 1 (HR = 0.78; 95% CI: 0.71–0.86) groups. Furthermore, it was worth noting that when subgroup analysis of gender was performed, compared with the control group, treatment with PD-1/PD-L1 inhibitors in the male subgroup was associated with significant clinical effectiveness in OS improvement (HR = 0.78; \( p < 0.001 \)), while no statistical difference was observed in the female segment between the two groups (\( p = 0.120 \)). In terms of
TABLE 2 Subgroup analysis of overall survival.

| Subgroup analysis                        | No. of studies | HR    | 95%CI  | p   | Heterogeneity (I2) (%) |
|-----------------------------------------|----------------|-------|--------|-----|------------------------|
| Line of therapy                         |                |       |        |     |                        |
| First line                               | 9              | 0.80  | 0.75–0.86 | <0.001 | 33.2                   |
| Non-first line                           | 7              | 0.81  | 0.69–0.95 | 0.010 | 68.8                   |
| Therapeutic schedules                    |                |       |        |     |                        |
| PD-1/PD-L1 + Chemotherapy vs. Chemotherapy | 8              | 0.75  | 0.68–0.82 | <0.001 | 46.0                   |
| PD-1/PD-L1 vs. Chemotherapy              | 9              | 0.87  | 0.80–0.96 | 0.003 | 30.0                   |
| Tumour types                             |                |       |        |     |                        |
| E                                        | 9              | 0.75  | 0.70–0.81 | <0.001 | 3.4                    |
| GEJ                                      | 7              | 0.87  | 0.76–0.99 | 0.040 | 0                      |
| G                                        | 7              | 0.87  | 0.77–0.98 | 0.019 | 57.2                   |
| Histological type (E/GEJ)               |                |       |        |     |                        |
| Adenocarcinoma                           | 2              | 0.92  | 0.61–1.38 | 0.679 | 73.3                   |
| Squamous cell carcinoma                  | 2              | 0.75  | 0.65–0.86 | <0.001 | 0                     |
| Lauren classification (G/GEJ)            |                |       |        |     |                        |
| Intestinal type                          | 5              | 0.80  | 0.71–0.92 | 0.001 | 12.9                   |
| Diffuse type                             | 5              | 0.84  | 0.72–0.99 | 0.032 | 43.7                   |
| Age                                      |                |       |        |     |                        |
| < 65 years                               | 15             | 0.81  | 0.75–0.87 | <0.001 | 20.4                   |
| ≥ 65 years                               | 15             | 0.80  | 0.73–0.88 | <0.001 | 32.7                   |
| ECOG performance status                  |                |       |        |     |                        |
| 0                                        | 14             | 0.82  | 0.73–0.91 | <0.001 | 39.2                   |
| 1                                        | 14             | 0.78  | 0.71–0.86 | <0.001 | 46.9                   |
| Sex                                      |                |       |        |     |                        |
| Male                                     | 15             | 0.78  | 0.72–0.84 | <0.001 | 43.4                   |
| Female                                   | 15             | 0.92  | 0.84–1.02 | 0.120 | 0                      |
| Geographical region                      |                |       |        |     |                        |
| Asia                                     | 15             | 0.75  | 0.68–0.82 | <0.001 | 44.2                   |
| Non-Asia                                 | 10             | 0.90  | 0.83–0.97 | 0.006 | 17.2                   |
| TPS                                      |                |       |        |     |                        |
| TPS < 1%                                 | 8              | 0.89  | 0.80–0.99 | 0.030 | 3.0                    |
| TPS ≥ 1%                                 | 9              | 0.69  | 0.58–0.83 | <0.001 | 35.0                   |
| TPS < 5%                                 | 4              | 0.78  | 0.68–0.89 | <0.001 | 0                      |
| TPS ≥ 5%                                 | 4              | 0.62  | 0.52–0.74 | <0.001 | 0                      |
| TPS < 10%                                | 5              | 0.77  | 0.68–0.86 | <0.001 | 0                      |
| TPS ≥ 10%                                | 4              | 0.66  | 0.52–0.83 | <0.001 | 0                      |
| CPS                                      |                |       |        |     |                        |
| CPS < 1                                 | 4              | 0.91  | 0.72–1.15 | 0.416 | 0                      |
| CPS ≥ 1                                 | 7              | 0.77  | 0.72–0.84 | <0.001 | 0                      |
| CPS < 5                                 | 2              | 0.87  | 0.70–1.08 | 0.221 | 29.7                   |
| CPS ≥ 5                                 | 3              | 0.71  | 0.63–0.79 | <0.001 | 0                      |
| CPS < 10                                | 5              | 0.86  | 0.74–0.99 | 0.038 | 22.3                   |
| CPS ≥ 10                                | 8              | 0.68  | 0.61–0.77 | <0.001 | 0                      |

HR, hazard ratio; CI, confidence interval; ECOG, Eastern Cooperative Oncology Group; PD-1, programmed death-1 receptor; PD-L1, programmed death ligand-1; TPS, PD-L1 tumour proportion score; CPS, PD-L1 combined positive score; E, esophageal cancer; GEJ, gastroesophageal junction cancer; G, gastric cancer.

geographical region, Asian (HR = 0.75; 95% CI: 0.68–0.82) and non-Asian (HR = 0.90; 95% CI: 0.83–0.97) patients demonstrated longer OS with PD-1/PD-L1 inhibitors compared with controls. However, the results also showed that the Asian population tended to have superior treatment efficacy with PD-1/PD-L1 inhibitors therapy compared with non-Asian patients. Table 2 displays the relevant outcome values.

To determine the impact of PD-L1 expression on treatment efficacy, PD-L1 tumor proportion score (TPS) and PD-L1 combined positive score (CPS) was chosen as the evaluation indicators. When 1% of TPS was used as the cutoff, the results showed that the OS of patients (esophageal cancer, gastroesophageal junction cancer and gastric cancer) in the TPS ≥1% group (HR = 0.69; 95% CI: 0.58–0.83) and TPS <1% group (HR = 0.89; 95% CI: 0.80–0.99) was superior to the control group, with patients of TPS ≥1% benefiting more from PD-1/PD-L1 inhibitors. When a TPS of 5% was used as the threshold, the results showed that patients with TPS <5% (HR = 0.78; 95% CI: 0.68–0.89) and TPS ≥5% (HR = 0.62; 95% CI: 0.52–0.74) had better OS compared with controls and that the TPS ≥5% group demonstrated greater OS benefit. Further, when a TPS of 10% was used as the cutoff point, compared with the control group, significant improvements in OS were observed in both groups with TPS <10% (HR = 0.77; 95% CI: 0.68–0.89) and TPS ≥10% (HR = 0.66; 95% CI: 0.52–0.83), with TPS ≥10% group showing greater benefit with PD-1/PD-L1 inhibitors compared with the TPS <10% group.

When CPS <1 or ≥1 was used as the threshold, the results showed that patients with CPS ≥1 (HR = 0.77, p < 0.001) had greater OS prolongation with PD-1/PD-L1 inhibitors compared with
controls, while no statistical difference was found between patients with CPS < 10 among the experimental and control group (p = 0.416). For CPS subgroups < 5 or ≥ 5, compared to the control group, a significant prolongation in OS was observed in patients with CPS ≥ 5 (HR = 0.71; p < 0.001), while no statistical difference was detected in the patients with CPS < 5 between the experimental and control groups (p = 0.221). Lastly, for CPS subgroups < 10 or ≥ 10, a greater improvement in OS with PD-1/PD-L1 inhibitors was observed for patients with CPS ≥ 10 (HR = 0.68; 95%CI: 0.61–0.77) and CPS < 10 (HR = 0.86; 95%CI: 0.74–0.99) compared with the control group, with the CPS ≥ 10 group demonstrating more benefit from PD-1/PD-L1 inhibitors. The results of the pooled effects are shown in Table 2.

### Progression-free survival outcomes

Altogether, there were 15 RCTs investigating PFS. A high heterogeneity between the included studies was observed, and the pooled PFS outcomes indicated no significant difference between the PD-1/PD-L1 inhibitor and control group (HR = 0.89; 95% CI: 0.75–1.06; I² = 91.1%; p = 0.185). The pooled effects of the overall cohort of the 15 studies are shown in Table 3.

Regarding subgroup analysis for therapeutic schedules, in comparison with the control group, PD-1/PD-L1 inhibitor combined with chemotherapy was found to markedly prolong PFS (HR = 0.68; p < 0.001), whereas the difference was not statistically significant with PD-1/PD-L1 inhibitor monotherapy between the experimental and control group (p = 0.146). Among all the subgroups of tumor types, consisting of esophageal cancer (HR = 0.78; p = 0.015), gastroesophageal junction cancer (p = 0.755) and gastric cancer (p = 0.759), when compared with the control group, only esophageal cancer patients had substantial improvement in PFS. Subgroup analysis based on therapy lines, ECOG performance status and geographical region showed that compared with controls, treatment with PD-1/PD-L1 inhibitors did not improve the PFS of patients with first-line therapy (p = 0.062) or non-first-line therapy (p = 0.901), ECOG performance status of 0 (p = 0.208) or 1 (p = 0.088) and Asian population (p = 0.301) or non-Asian population (p = 0.681). For patients’ age, the analysis revealed that those aged ≥ 65 years old (HR = 0.74; p = 0.049) had longer PFS than controls, while no significant difference was observed in patients aged < 65 years old (p = 0.179) among the two groups. In addition, consistent with the above analysis of OS in terms of gender, when the subgroups were distinguished by gender, compared with the control group,
therapy with PD-1/PD-L1 inhibitors was associated with significant PFS improvement in the experimental group of male patients (HR = 0.71; \( p = 0.037 \)), while no significant statistical difference was observed in female patients among the experimental and control group (\( p = 0.932 \)). For the influence of PD-L1 expression on efficacy, when TPS was chosen as the predictive marker, the differences were not statistically significant for TPS between the experimental and control group, nor for groups of TPS <1% (\( p = 0.863 \)) or TPS \( \geq 1\% \) (\( p = 0.720 \)). When CPS was used as the predictive marker, compared with the control group, a significant improvement with PD-1/PD-L1 inhibitors on PFS was observed only in patients with CPS <10 (HR = 0.68; \( p = 0.031 \)) or CPS \( \geq 10 \) (HR = 0.72; \( p = 0.005 \)), while no statistical difference was found in both groups of CPS <1 (\( p = 0.297 \)) or CPS \( \geq 1 \) (\( p = 0.671 \)) between the experimental group and the control group. The pooled effects in all subgroups are shown in Table 3.

### Effect of overall survival in subgroups of age and sex

To further explore the influence of age and gender on the clinical efficacy of PD-1/PD-L1 inhibitors, variables including lines of therapy, therapeutic schedules and tumor types were merged for pooled analysis. The results showed that both subgroups of <65 or \( \geq 65 \) years demonstrated significantly prolonged OS with PD-1/PD-L1 inhibitors compared with the control group. The detailed data are shown in Table 4.

However, when the sex subgroup was analyzed, compared with the control group, the data revealed a substantial improvement in OS for males in lines of therapy, therapeutic schedules and tumor types, while females had no statistical difference in any of the investigated categories between the experimental and control group. Table 5 comprises the detailed data.

| Subgroup analysis | HR   | 95% CI   | \( p \)  |
|-------------------|------|----------|----------|
| < 65 years        |      |          |          |
| First line        | 0.80 | 0.74–0.86| <0.001   |
| Non-first line    | 0.82 | 0.68–0.98| 0.028    |
| \( \geq 65 \) years |      |          |          |
| First line        | 0.81 | 0.73–0.90| <0.001   |
| Non-first line    | 0.77 | 0.62–0.96| 0.019    |
| < 65 years        |      |          |          |
| PD-1/PD-L1 + Chemotherapy vs. Chemotherapy | 0.77 | 0.71–0.84| <0.001   |
| PD-1/PD-L1 vs. Chemotherapy | 0.84 | 0.75–0.95| 0.004    |
| \( \geq 65 \) years |      |          |          |
| PD-1/PD-L1 + Chemotherapy vs. Chemotherapy | 0.77 | 0.67–0.88| <0.001   |
| PD-1/PD-L1 vs. Chemotherapy | 0.83 | 0.72–0.95| 0.009    |
| < 65 years        |      |          |          |
| E + GEJ           | 0.75 | 0.68–0.82| <0.001   |
| G + GEJ           | 0.87 | 0.77–0.98| 0.022    |
| \( \geq 65 \) years |      |          |          |
| E + GEJ           | 0.74 | 0.66–0.84| <0.001   |
| G + GEJ           | 0.87 | 0.74–1.03| 0.100    |

| Subgroup analysis | HR   | 95% CI   | \( p \)  |
|-------------------|------|----------|----------|
| Male              |      |          |          |
| First line        | 0.77 | 0.71–0.84| <0.001   |
| Non-first line    | 0.78 | 0.67–0.91| 0.002    |
| Female            |      |          |          |
| First line        | 0.92 | 0.82–1.03| 0.153    |
| Non-first line    | 0.89 | 0.66–1.21| 0.461    |
| Male              |      |          |          |
| PD-1/PD-L1 + Chemotherapy vs. Chemotherapy | 0.73 | 0.66–0.81| <0.001   |
| PD-1/PD-L1 vs. Chemotherapy | 0.82 | 0.74–0.90| <0.001   |
| Female            |      |          |          |
| PD-1/PD-L1 + Chemotherapy vs. Chemotherapy | 0.90 | 0.79–1.03| 0.141    |
| PD-1/PD-L1 vs. Chemotherapy | 0.94 | 0.79–1.11| 0.469    |
| Male              |      |          |          |
| E + GEJ           | 0.73 | 0.66–0.80| <0.001   |
| G + GEJ           | 0.84 | 0.75–0.95| 0.004    |
| Female            |      |          |          |
| E + GEJ           | 0.87 | 0.70–1.06| 0.171    |
| G + GEJ           | 0.99 | 0.87–1.14| 0.906    |
Publication bias and sensitivity analysis

To evaluate publication bias of OS in the general gastroesophageal cancer patients who were treated with PD-1/PD-L1 inhibitors, the quantification Begg’s test was employed. And the p value of Begg’s funnel plots was 0.509, indicating no potential publication bias among the included articles on HR for OS. The related data was shown in Supplementary Figures S3. Apart from that, sensitivity analysis was also performed to appraise the stability of HR for OS by omitting each study in sequence successively, and the results confirmed the excellent stability. The relevant data was comprised in Supplementary Figures S4.

Discussion

As a negative costimulatory receptor, PD-1 is expressed on activated T-cells and binds to the PD-L1 ligand to downregulate T-cell-mediated immune responses (Nishimura et al., 1999; Freeman et al., 2000; Greenwald et al., 2005). Therefore, due to the activation of the PD-1 signaling pathway and the overexpression of PD-L1 in tumor cells, malignant tumors can escape immune surveillance (Topalian et al., 2012; Comprehensive molecular characterization of gastric, 2014). Based on the above theoretical basis, blocking the related signal pathways with PD-1/PD-L1 inhibitors may restore the immune activity of T cells (Topalian et al., 2012; Comprehensive molecular characterization of gastric, 2014). In terms of pathophysiology, gastroesophageal cancer is not considered an immune-related type of cancer in the conventional sense. Nonetheless, several studies have revealed that the number of gastroesophageal tumor-infiltrating lymphocytes could be associated with the progression of the tumor and patients’ prognosis (Short et al., 2017; Zhu et al., 2017). Based on which PD-1/PD-L1 inhibitors have been investigated as a therapeutic strategy for advanced gastroesophageal cancer patients.

This present systematic review and meta-analysis was performed to investigate the clinical efficacy of PD-1/PD-L1 inhibitors on advanced gastroesophageal cancer as well as the relationship between clinicopathological features and the curative effects of PD-1/PD-L1 inhibitors. Consistent with the results of previous meta-analyses (Chen et al., 2021; Formica et al., 2021; Oh et al., 2021), we found that PD-1/PD-L1 inhibitors (monotherapy or combined with chemotherapy) were associated with a prolongation of OS in patients with esophageal cancer, gastroesophageal junction cancer and gastric cancer, and it should be emphasized that no significant improvement in PFS was observed. Although both OS and PFS are regarded as important survival outcomes of response efficacy in anticancer treatment, the link between the two has yet to be fully proved. OS is defined as the time from randomization to death from any cause, with the outcome measure being time to death. Due to longer follow-up duration, patients’ OS is more susceptible to further treatment, cross-treatment, and other diseases. Nonetheless, for clinical oncology trials, since the goal of cancer treatment is to prolong survival, OS remains the gold standard for reflecting the endpoint of curative effect in cancer treatment (Fiteni et al., 2014; Sarac et al., 2019). Compared with OS, the follow-up duration of PFS is significantly prolonged and has been used as a favorable surrogate endpoint for OS in different cancer therapies such as chemotherapy, radiotherapy, targeted therapy, etc. However, in the field of immunotherapy, whether PFS performs better than traditional response evaluation criteria such as OS in evaluating efficacy or clinical benefits has not been verified in clinical trial settings (Zhu et al., 2021). Besides, several studies have demonstrated that advanced esophageal cancer patients with biomarker differences including no 11q13 chromosomal amplification, high tumor mutation burden (TMB), and microsatellite instability-high (MSI-H) tended to have greater OS rather than PFS benefit from PD-1/PD-L1 inhibitors (Mocellin et al., 2001; Greally and Ku, 2018; Lu et al., 2021). As a result, OS might be a better curative effect endpoint in evaluating the clinical efficacy of PD-1/PD-L1 inhibitors in advanced gastroesophageal cancer to some extent.

In line with recent studies, ICIs therapy might still be beneficial in patients with various malignancies, including gastroesophageal cancer. However, the low response rates in patients with advanced cancer and the reduced incidence of immune-related adverse events in unresponsive patients remain the major obstacles to treating cancer with immune checkpoint therapy (Darvin et al., 2018). Therefore, to facilitate patient selection and decision-making of PD-1/PD-L1 inhibitors therapy, further research into highly reliable predictive markers is required. The subgroup analysis of this present study showed that patients with esophageal cancer, gastroesophageal junction cancer and gastric cancer could benefit from PD-1/PD-L1 inhibitors treatment in both first-line and non-first-line therapy. Previously, although there have been numerous studies on the usage of PD-1/PD-L1 inhibitors in the treatment of gastroesophageal cancer worldwide, none has been officially approved by the FDA. However, it is worth noting that there have been some recent breakthroughs in this field. In May 2021, the FDA approved nivolumab in combination with chemotherapy as first-line therapy for advanced or metastatic esophageal adenocarcinoma, gastroesophageal junction cancer and gastric cancer, representing the first time a new treatment for stage II/III gastroesophageal cancer has been approved apart from chemotherapeutics (Weadick et al., 2022). The results of this present study also provide some evidence for more PD-1/PD-L1 inhibitors to be assessed as first-line treatment in gastroesophageal cancer. Further, it was reported that because patients receiving first-line treatment might have better performance status than those receiving non-first-line treatment, they might respond more favorably to immunotherapy (Reck et al., 2019). Nevertheless, our study.
showed consistent efficacy between the first-line and non-first-line treatments. As for ECOG performance status, our results demonstrated that it might not be a key factor affecting the efficacy of PD-1/PD-L1 inhibitors, as improvements in OS were observed in both subgroups of ECOG performance status.

For therapeutic schedules, some studies demonstrated that PD-1/PD-L1 inhibitors in combination with chemotherapy could promote tumor antigen cross-presentation and up-regulate the expression of major histocompatibility complex (MHC) class I antigens (Serrano et al., 2001). In addition, in the presence of interleukin (IL)-2, IL-5 and other cytokines, increasing the activation of CD8+ T-cells with PD-1/PD-L1 inhibitors combined with chemotherapy was shown to further improve its tumor-killing ability compared with chemotherapy (Serrano et al., 2001). Hence, consistent with previous clinical studies (Janjigian et al., 2021; Doki et al., 2022; Kang et al., 2022), our results also support the combination of PD-1/PD-L1 inhibitors with chemotherapy to potentially prolong the patients’ OS and PFS.

Gastroesophageal cancer is an umbrella term for tumors with extensive heterogeneity among different histologic types and tumor topographical locations. Anatomically, it can be subdivided into esophageal cancer, gastroesophageal junction cancer and gastric cancer. Our results showed that PD-1/PD-L1 inhibitors significantly improved the OS and PFS of esophageal cancer patients compared with those having gastroesophageal junction and gastric cancer. For gastroesophageal junction cancer, previous studies showed that in terms of clinical and pathological features, gastroesophageal junction cancer in Chinese patients was mainly associated with proximal gastric cancer, compared with distal esophageal cancer in American patients (Huang et al., 2011; Chevallay et al., 2018). Therefore, the therapeutic schedules for advanced gastroesophageal junction cancer remain controversial. According to our analysis, PD-1/PD-L1 inhibitors had similar OS improvement in gastroesophageal junction cancer, gastric cancer, and esophageal cancer. In regard to the histological subtypes of esophageal cancer, the Japanese Endoscopy Society and The Cancer Genomic Atlas (TCGA) categorizes it as adenocarcinoma and squamous cell carcinoma (Japanese classification of gastric carcinoma, 2011; Comprehensive molecular characterization of gastric, 2014). For gastric cancer, adenocarcinoma accounts for 95% of all gastric cancer cases and is classified as intestinal (with intracellular junctions) or diffuse (without intracellular junctions) based on the Lauren classification (Lauren, 1965). Further, it was reported that the overexpression of PD-L1 might be related to better efficacy of PD-1/PD-L1 inhibitors (Vrána et al., 2018) and that the overexpression of PD-L1 was greater in esophageal squamous cell carcinoma than in esophageal adenocarcinoma and gastric adenocarcinoma (including intestinal and diffuse type) (Maoshi et al., 2021). According to our data analysis, this might be one of the reasons why esophageal squamous cell carcinoma demonstrated more effective treatment efficacy with PD-1/PD-L1 inhibitors compared with esophageal adenocarcinoma and gastric cancer.

Intriguingly, subgroup analysis on age demonstrated that PD-1/PD-L1 inhibitors could considerably prolong the OS of gastroesophageal cancer patients regardless of the patient’s age. In general, aging significantly impacts normal cells in the tumor microenvironment, causing frailty in older patients to limit their capacity to receive further treatment (Landre et al., 2020). However, after the variables including line of therapy, therapeutic schedules, and tumor types were merged with age for pooled analysis, significant potential curative effects with PD-1/PD-L1 inhibitors were observed in the <65 or ≥65 years subgroups. A previous meta-analysis targeted at age also revealed that in the first line treatment, PD-1/PD-L1 inhibitors were effective not only for patients aged <75 years, but also for patients aged >75 years (Landre et al., 2020). Thus, the upper age limit of PD-1/PD-L1 inhibitors might need to be re-assessed in the future. Due to the limited treatment options for advanced gastroesophageal cancer in the elderly, PD-1/PD-L1 inhibitors could be considered as a potentially effective treatment option.

The most notable finding of this study was that when subgroup analysis was performed on gender, the results illustrated that for gastroesophageal cancer patients, compared to chemotherapy, PD-1/PD-L1 inhibitors were associated with OS and PFS benefits in males but not in females (i.e., immunotherapy was more effective in males). When lines of therapy, therapeutic schedules and tumor types were pooled with sex for pooled analysis, the findings still supported this trend. Conforti et al. (2018) reported that PD-1/PD-L1 inhibitors could improve the OS of males and females with advanced or metastatic cancer, though male patients had a twofold reduction in mortality risk compared with females. The phenomenon might be interpreted by the fact that compared with males, the MHC-based presentation of driver mutations might be poorer in females; therefore, even if T-cells restore the anti-tumor immune activity under the action of PD-1/PD-L1 inhibitors, triggering the appropriate immune killing response might be more challenging in females than in males (Dinesh et al., 2010; Castro et al., 2020). Another reason might be closely related to the TMB, defined as the total number of nonsynonymous mutations detected per million bases. TMB has emerged as a biomarker for predicting the efficacy of PD-1/PD-L1 inhibitors in several cancers (Snyder et al., 2014; Rizvi et al., 2015). It was even reported that the TMB of men was higher than women in melanoma and non-small cell lung cancer, indicating that the tumor cells of male patients could be more antigenic and respond better to PD-1/PD-L1 inhibitors, resulting in superior curative effects (Gupta et al., 2015; Wang et al., 2019a; Wang et al., 2019b). Additionally, behavioral differences between males and females, such as a higher frequency of smoking and alcohol abuse in males, might also impact the human body's...
internal environment, leading to sex differences in immune responses to a certain extent. However, recent studies have shown that a large number of androgens secreted by men could induce the exhaustion of CD8+ T-cell, thereby losing their anticancer activity (Kwon et al., 2022; Yang et al., 2022). Thus, blocking the androgen-androgen receptor axis could reshape the tumor microenvironment, facilitate the differentiation of effector T-cells and enhance the therapeutic effect of anti-PD-1 immune checkpoint blockade. Moreover, due to the gender imbalance in the study, the relationship between gender and PD-1/PD-L1 inhibitors treatment still needs to be further investigated.

With regard to geographical region, this study indicated that the efficacy of PD-1/PD-L1 inhibitors in the Asian gastroesophageal cancer population appeared to be better than that of the non-Asian population, which was consistent with the results of a previous meta-analysis (Formica et al., 2021). For non-Asian patients, risk factors such as obesity, smoking, and alcohol consumption are mostly responsible for the occurrence of gastroesophageal cancer (Chow et al., 1995; Lagergren et al., 1999; Wu et al., 2003; Hoyo et al., 2012). However, in the Asian population, Helicobacter pylori infection is regarded as a high-risk factor for gastric cancer and esophageal squamous cell carcinoma (Ye et al., 2004; Crew and Neugut, 2006; Rahman et al., 2014). Recent studies indicated that chronic H. pylori infection could induce gastric epithelial cells in patients with negative PD-L1 expression to express PD-L1 while causing local inflammation, reshaping the tumor microenvironment, and making local immune cells more likely to be activated to better respond to ICIs (Wu et al., 2010; Lubin et al., 2012). As a result, due to the high prevalence of H. pylori infection in Asian populations, compared with non-Asian populations, Asian populations may have greater efficacy for PD-1/PD-L1 inhibitors to a certain extent (Eusebi et al., 2014; Flores-Treviño et al., 2018).

This study also showed that although the OS of both TPS and CPS was prolonged with PD-1/PD-L1 inhibitors, TPS did not appear to adequately illustrate the relation between PD-L1 expression and treatment efficacy. When CPS <1, <5, and <10 were used, the results were statistically insignificant. Comparatively, TPS measures PD-L1 expression based on tumor ratio only (Dolled-Filhart et al., 2016), while CPS is defined as the ratio of all cells associated with PD-L1 expression to the total number of tumor cells. CPS has also been shown to be superior to the original TPS as a robust and reproducible PD-L1 scoring method after clinical verification (Kulangara et al., 2019; Weadick et al., 2022). Overall, CPS might outperform TPS in PD-L1 expression and treatment efficacy with PD-1/PD-L1 inhibitors in advanced gastroesophageal cancer.

In conclusion, this meta-analysis provides an update on the potential influencing factors such as treatment strategy, gender and PD-L1 expression in patients with gastroesophageal cancer treated with PD-1/PD-L1 inhibitors. Although earlier studies were performed on predictive markers, including gender and PD-L1 expression (Formica et al., 2021), however, due to the limited number of studies previously investigated, significant heterogeneity in the obtained results and discrepancies in different evaluation indicators of PD-L1 expression (i.e., TPS, CPS), an update on the significance of PD-1/PD-L1 inhibitors in gastroesophageal cancer was urgently needed. In this present study, more recent RCTs were included in the analyses, thereby providing new evidences and support for the clinical efficacy of PD-1/PD-L1 inhibitors in gastroesophageal cancer. Nevertheless, there were several limitations in this study that should be mentioned. First, the population covered in the study had an unbalanced gender ratio. Therefore, more studies should be conducted on the correlation between gender and PD-1/PD-L1 inhibitors efficacy in patients with gastroesophageal cancer. Second, although TMB and MSI-H were both biomarkers indicating better efficacy of PD-1/PD-L1 inhibitors, we cannot perform subgroup analysis of TMB and MS-H on account of unavailable data. Third, due to the limited number of studies, we were unable to perform subgroup analysis of other therapeutic schedules such as PD-1/PD-L1 inhibitors versus targeted therapy, PD-1/PD-L1 inhibitors versus radiotherapy, etc. Fourth, since few included studies further classified gastroesophageal junction cancer (e.g., Siewert classification or Nishi classification), we could not conclude the impact of PD-1/PD-L1 inhibitors on the efficacy of different types of gastroesophageal junction cancer.

**Conclusion**

In conclusion, this meta-analysis demonstrates that PD-1/PD-L1 inhibitors (monotherapy or combined with chemotherapy) were associated with a prolongation of OS in patients with advanced gastroesophageal cancer, while there was no significant difference in the improvement of PFS. For clinicopathological features, evaluation indicators including therapeutic schedules, tumour types, histological type, sex, geographical region and PD-L1 expression status (TPS and CPS) seemed to be relevant to survival outcomes. Besides, therapy line, Lauren classification, age and ECOG performance status may not be the pivotal factors influencing the efficacy of PD-1/PD-L1 inhibitors. Based on considerations of relevant limitations, large sample RCTs are still needed to further confirm the study conclusion.

**Data availability statement**

The original contributions presented in the study are included in the article/Supplementary Material, further inquiries can be directed to the corresponding authors.
Author contributions

LG, NH designed the research process, PC, TH searched the database for corresponding articles and drafted the meta-analysis. SQ, NH extracted useful information from the articles above. JH, RF used statistical software for analysis. CN, SD polished this article. All authors contributed to manuscript revision, read, and approved the submitted version.

Funding

This study was funded by Zhejiang Provincial Key Laboratories (Grant No. 2019E10020), China, and Ningbo Clinical Research Center for Digestive System Tumors (Grant No. 2019A21003) and Ningbo Medical Key Discipline (Grant No. 2022-B09).

Conflict of interest

The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.

References

Ajani, J. A., D’Amico, T. A., Almanna, K., Bentrem, D. J., Chao, J., Das, P., et al. (2016). Gastric cancer, version 3.2016, NCCN clinical practice Guidelines in oncology. J. Natl. Compr. Canc. Netw. 14 (10), 1286–1312. doi:10.6099/jnccn.2016.0137

Bang, Y. J., Ruiz, E. Y., van Cutsem, E., Lee, K. W., Wyrwicz, L., Schenker, M., et al. (2018). Phase III, randomised trial of avelumab versus physician’s choice of chemotherapy as third-line treatment of patients with advanced gastric or gastroesophageal junction cancer: Primary analysis of JAVELIN gastric 300. Ann. Oncol. 29 (10), 2052–2060. doi:10.1093/annonc/mdy264

Boku, N., Satoh, T., Ryu, M.-H., Chao, Y., Kato, K., Chung, H. C., et al. (2021). Nivolumab in previously treated advanced gastric cancer (ATTRACTION-2): 3-year update and outcome of treatment beyond progression with nivolumab. Gastric Cancer 24 (4), 946–958. doi:10.1007/s10120-021-01173-w

Bray, F., Ferlay, J., Soerjomataram, I., Siegel, R. L., Torre, L. A., and Jamal, A. (2018). Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. Ca. Cancer J. Clin. 68 (6), 394–424. doi:10.3322/caac.21492

Castro, A., Pyke, R. M., Zhang, X., Thompson, W. K., Day, C.-P., Alexandrov, L. B., et al. (2020). Strength of immune selection in tumors varies with sex and age. Nat. Commun. 11 (1), 4128. doi:10.1038/s41467-020-17981-0

Chen, K., Wang, X., Yang, L., and Chen, Z. (2021). The anti-PD-1/PD-L1 immunotherapy for gastric esophageal cancer: A systematic review and meta-analysis and literature review. Cancer Control. 28, 1073274819974340. doi:10.1177/1073274819974340

Chevalley, M., Bollschweiler, E., Chandramohan, S. M., Schmidt, T., Koch, O., Demanzoni, G., et al. (2018). Cancer of the gastroesophageal junction: A diagnosis, classification, and management review. Ann. N. Y. Acad. Sci. 1434 (1), 132–138. doi:10.1111/nyas.13954

Chow, W. H., Finkle, W. D., McLaughlin, J. K., Frankl, H., Ziel, H. K., and Fraumeni, J. F. (1995). The relation of gastroesophageal reflux disease and its treatment to adenocarcinomas of the esophagus and gastric cardia. JAMA 274 (6), 474–477. doi:10.1001/jama.1995.0350060048032

Chung, H. C., Kang, Y.-K., Chen, Z., Bai, Y., Wan Ishak, W. Z., Shim, B. Y., et al. (2022). Pembrolizumab versus paxilatxel for previously treated advanced gastric or gastroesophageal junction cancer (KEYNOTE-063). A randomized, open-label, phase 3 trial in asian patients. Cancer 128 (5), 995–1003. doi:10.1002/cncr.34019

Comprehensive molecular characterization of gastric adenocarcinoma. Nature. 2014;513(7517):202–209. doi:10.1038/nature13480

Conforti, F., Pala, L., Bagnardi, V., De Pas, T., Martinetti, M., Viale, G., et al. (2018). Cancer immunotherapy efficacy and patients’ sex: A systematic review and meta-analysis. Lancet. Oncol. 19 (6), 737–746. doi:10.1016/S1470-2045(18)30261-4

Crew, K. D., and Neugut, A. I. (2006). Epidemiology of gastric cancer. World J. Gastroenterol. 12 (3), 534–562. doi:10.3748/wjg.v12.i3.534

Davin, P., Toor, S. M., Sasidharan Nair, V., and Elkord, E. (2018). Immune checkpoint inhibitors: Recent progress and potential biomarkers. Exp. Mol. Med. 50 (12), 1–11. doi:10.1038/s41227-018-0191-1

Dinesh, R. K., Hahn, B. H., and Singh, R. P. (2010). PD-1, gender, and autoimmunity. Autoimmun. Rev. 9 (8), 583–587. doi:10.1016/j.autrev.2010.04.003

Doki, Y., Ajani, J. A., Kato, K., Xu, J., Wyrwicz, L., Motoyama, S., et al. (2022). Nivolumab combination therapy in advanced esophageal squamous-cell carcinoma. N. Engl. J. Med. 386 (5), 449–462. doi:10.1056/NEJMoa2111380

Dollé-Fihart, M., Locke, D., Murphy, T., Lynch, F., Yearley, J. H., Frisman, D., et al. (2016). Development of a prototype immunohistochemistry assay to measure programmed death ligand-1 expression in tumor tissue. Arch. Pathol. Lab. Med. 140 (11), 1259–1266. doi:10.5858/arpa.2015-0544-OA

Fusetani, F., Wested, J., Provot, X., Borg, C., Vernerey, D., and Bonnetotan, F. (2014). Endpoints in cancer clinical trials. J. Visc. Surg. 151 (1), 17–22. doi:10.1016/j.jviscsurg.2013.10.001

Flores-Treviño, S., Mendoza-Olazarán, S., Bocanegra-Ibarias, P., Maldonado-Garza, H. J., and Garza-González, F. (2018). Helicobacter pylori drug resistance: Therapy changes and challenges. Exp. Rev. Gastroenterol. Hepatol. 12 (8), 819–827. doi:10.1080/17474124.2018.1496017

Publisher’s note

All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article, or claim that may be made by its manufacturer, is not guaranteed or endorsed by the publisher.

Supplementary material

The Supplementary Material for this article can be found online at: https://www.frontiersin.org/articles/10.3389/fphar.2022.1009254/full#supplementary-material

SUPPLEMENTARY FIGURE S1

Quality assessment of studies included in this meta-analysis (risk of bias graph).

SUPPLEMENTARY FIGURE S2

Quality assessment of studies included in this meta-analysis (Risk of bias summary).

SUPPLEMENTARY FIGURE S3

The p value of Begg’s funnel plots for publication bias.

SUPPLEMENTARY FIGURE S4

Sensitivity analysis of the hazard ratios of overall survival.
Formica, V., Morelli, C., Patriladou, A., Shau, K. K., Nardocchia, A., Lucchetti, J., et al. (2021). A systematic review and meta-analysis of PD-1/PD-L1 inhibitors in specific patient subgroups with advanced gastro-oesophageal junction and gastric adenocarcinoma. Crit. Rev. Oncol. Hematol. 157, 103173. doi:10.1016/j.critrevonc.2020.103173

Freeman, G. J., Long, A. J., Iwai, Y., Bourque, K., Chernova, T., Nishimura, H., et al. (2000). Engagement of the PD-1 immunoinhibitory receptor by a novel B7 family member leads to negative regulation of lymphocyte activation. J. Exp. Med. 192 (7), 1027–1034. doi:10.1084/jem.192.7.1027

Fuchs, C. S., Östergård, M., Bang, V. J., Di Bartolomeo, M., Mandalà, M., Ryu, M.-H., et al. (2022). Pembrolizumab versus paclitaxel for previously treated PD-L1 positive advanced gastric or gastroesophageal junction cancer: 2-year update of the randomized phase 3 KEYNOTE-061 trial. Gastric Cancer 25 (1), 197–206. doi:10.1007/s10120-021-01227-4

Greally, M., and Ku, G. Y. (2018). Immune checkpoint inhibitors in esophageal adenocarcinoma: Do the results justify the hype? J. Thorac. Dis. 10 (12), 6407–6411. doi:10.3329/jtd.v10i12.28128

Greenwald, R. J., Freeman, G. J., and Sharpe, A. H. (2005). The B7 family revisited. Immune checkpoint inhibitors for patients aged ≥75 Years with advanced cancer in first- and second-line settings: A meta-analysis. Drugs Aging 37 (10), 747–754. doi:10.1007/s12026-020-00798-5

Lauren, P. (1965). The two histological main types of gastric carcinoma. Diffuse and so-called intestinal-type carcinoma. An attempt at a histo-clinical classification. Acta Pathol. Microbiol. Scand. 64, 31–49. doi:10.1111/apm.1965.641.131

Lu, Y., Guan, L., Xu, M., and Wang, F. (2021). The efficacy and safety of antibodies targeting PD-1 for treatment in advanced esophageal cancer: A systematic review and meta-analysis. Transl. Oncol. 14 (6), 101083. doi:10.1016/j.tranon.2021.101083

Lubin, J. H., Cook, M. B., Pandeya, N., Vaughan, T. L., Abnet, C. C., Giffen, C., et al. (2012). The importance of exposure rate on odds ratios by cigarette smoking and alcohol consumption for esophageal adenocarcinoma and squamous cell carcinoma in the Barrett’s Esophagus and Esophageal Adenocarcinoma Consortium. Cancer Epidemiol. 36 (3), 306–316. doi:10.1016/j.canep.2012.03.001

Luo, H., Lu, J., Bai, Y., Mao, T., Wang, J., Fan, Q., et al. (2021). Effect of camrelizumab vs placebo added to chemotherapy on survival and progression-free survival in patients with advanced or metastatic esophageal squamous cell carcinoma: The ESCORT-1st randomized clinical trial. JAMA 326 (10), 916–925. doi:10.1001/jama.2021.12836

Maoni, Z., Jinmin, X., Xiaohua, Z., Yubing, Y., and Yuji, Z. (2021) PD-1/PD-L1 inhibitors versus chemotherapy for previously treated advanced gastric cancer: A meta-analysis of randomized controlled trials. J. Clin. Oncol. 39, 3049–3054. doi:10.1002/jco.29307

Meoher, M., Dvorkin, M., Boku, N., Östergård, M., Ryu, M.-H., Muntean, A., et al. (2021). Phase III trial of avelumab maintenance after first-line induction chemotherapy versus continuation of chemotherapy in patients with gastric cancers: Results from JAVELIN gastric 100. J. Clin. Oncol. 39 (9), 968–977. doi:10.1200/JCO.20.00892

Mohler, D., Shamseer, L., Clarke, M., Gheri, D., Liberati, A., Petticrew, M., et al. (2015). Preferred reporting items for systematic review and meta-analysis protocols (PRISMA-P) 2015 statement. Systematic Rev. 4, 1. doi:10.1186/s13643-015-0049-8

Ni, X., Xing, Y., Sun, X., and Suo, J. (2020). The safety and efficacy of anti-PD-1/anti-PD-L1 antibody therapy in the treatment of previously treated, advanced gastric or gastro-oesophageal junction cancer: A meta-analysis of prospective clinical trials. Clin. Res. Hæpatol. Gastroenterol. 44 (2), 221–222. doi:10.1016/j.clinre.2019.05.007

Nishimura, H., Nose, M., Hai, H., Minato, N., and Honjo, T. (1999). Development of lupus-like autoimmune diseases by disruption of the PD-1 gene encoding an ITIM motif-carrying immunoreceptor. Immunity 11 (2), 141–151. doi:10.1016/S1074-7613(00)80089-9

Nishizuka, S. S., Tamura, G., Nakatochi, M., Fukushima, N., Ohmori, Y., Sumida, Y., et al. (2018). Helicobacter pylori infection is associated with favorable outcome in advanced gastric cancer patients treated with S-1 adjuvant chemotherapy. J. Surg. Oncol. 117 (5), 947–956. doi:10.1002/jso.24977

Oh, S., Kim, E., and Lee, H. (2021). Comparative impact of PD-1 and PD-L1 inhibitors on advanced esophageal or gastro/gastric/esophageal junction cancer treatment: A systematic review and meta-analysis. J. Clin. Med. 10 (16), 3612. doi:10.3390/jcm10163612

Okada, M., Kato, K., Cho, B. C., Takahashi, M., Lin, C-Y., Chin, K., et al. (2022). Pembrolizumab versus platinum-based chemotherapy for advanced non-small-cell lung cancer with PD-L1 tumor proportion score of 50% or greater. J. Clin. Oncol. 37 (7), 537–546. doi:10.1200/JCO.18.00149

Lagregn, J., Bergström, R., Lindgren, A., and Nyrén, O. (1999). Symptomatic gastroesophageal reflux as a risk factor for esophageal adenocarcinoma. N. Engl. J. Med. 340 (11), 825–831. doi:10.1056/NEJM199903183401101

Landrè, T., Des Guetz, G., Chouaib, K., Fossay-Diaz, V., and Culine, S. (2020). Immune checkpoint inhibitors for patients aged ≥75 Years with advanced cancer in first- and second-line settings: A meta-analysis. Drugs Aging 37 (10), 747–754. doi:10.1007/s12026-020-00798-5

Reck, M., Rodriguez-Abren, D., Robinson, A. G., Hui, R., Cossia, T., Fülöp, A., et al. (2019). Updated analysis of KEYNOTE-042: Pembrolizumab versus platinum-based chemotherapy for advanced non-small-cell lung cancer with PD-L1 tumor proportion score of 50% or greater. J. Clin. Oncol. 37 (7), 537–546. doi:10.1200/JCO.18.00149
Rizvi, N. A., Hellmann, M. D., Snyder, A., Kostic, P., MAKAROV, V., Havel, J. J., et al. (2015). Cancer immunology. Mutational landscape determines sensitivity to PD-1 blockade in non-small cell lung cancer. Science 348 (6230), 124–128. doi:10.1126/science.aaa348

Sarac, B., Ainsworth, M. A., Hovgaard, D., and Bjerrum, O. W. (2019). Progression-free survival (PFS) in oncology: Caveat emptor. Basic Clin. Pharmacol. Toxicol. 124 (3), 237–238. doi:10.1111/bcpt.13192

Serrano, A., Taranzarella, S., Lionello, I., Mendez, R., Traversari, C., Ruiz-Cabello, F., et al. (2001). Expression of HLA class I antigens and restoration of antigen-specific CTL response in melanoma cells following 5-aza-2'-deoxycytidine treatment. Int. J. Cancer 94 (2), 243–251. doi:10.1002/ijc.1452

Sharma, P., and Allison, J. P. (2015). Immune checkpoint targeting in cancer therapy: Toward combination strategies with curative potential. Cell 161 (2), 205–214. doi:10.1016/j.cell.2015.03.030

Shen, Z., Gu, L., Mao, D., Chen, M., and Jin, R. (2019). Clinico-pathological and prognostic significance of PD-L1 expression in colorectal cancer: A systematic review and meta-analysis. World J. Surg. Oncol. 17 (1), 4. doi:10.1186/s12957-018-1544-x

Shitara, K., Van Cutsem, E., Bang, Y.-J., Fuchs, C., Wyrwicz, L., Lee, K-W., et al. (2014). Genetic basis for clinical response to CTLA-4 blockade in melanoma. Nat. Environ. Med. 371 (23), 2189–2199. doi:10.1056/NEJMoa1406498

Snyder, A., Makarov, V., Merghoub, T., Yuan, J., Zaretsky, J. M., Desrichard, A., et al. (2020). Efficacy and safety of pembrolizumab or tremelizumab plus chemotherapy vs chemotherapy alone for patients with first-line, advanced gastric cancer: The KEYNOTE-062 phase 3 randomized clinical trial. JAMA Oncol. 6 (10), 1571–1580. doi:10.1001/jamaoncol.2020.3370

Shopt, M. W., Burgers, K. G., and Fry, V. T. (2017). Esophageal cancer. Am. Fam. Physician 95 (11), 22–28.

Snyder, A., Makarov, V., Merghoub, T., Yuan, J., Zaretsky, J. M., Desrichard, A., et al. (2014). Genetic basis for clinical response to CTLA-4 blockade in melanoma. N. Engl. J. Med. 373 (23), 2189–2199. doi:10.1056/NEJMoa1406498

Sun, J.-M., Shen, L., Shah, M. A., Enzinger, P., Adenis, A., Dou, T., et al. (2021). Pembrolizumab plus chemotherapy versus chemotherapy alone for first-line treatment of advanced oesophageal cancer (KEYNOTE-590): A randomised, placebo-controlled, phase 3 study. Lancet 398 (10302), 759–771. doi:10.1016/S0140-6736(21)03124-4

Sung, H., Ferlay, J., Siegel, R. L., Laversanne, M., Soerjomataram, I., Jamal, A., et al. (2021). Global cancer statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. Ca. Cancer J. Clin. 71 (3), 209–249. doi:10.3322/caac.21660

Topalian, S. L., Hodi, F. S., Brahmer, J. R., Gettinger, S. N., Smith, D. C., McDermott, D. F., et al. (2012). Safety, activity, and immune correlates of anti-PD-1 antibody in cancer. N. Engl. J. Med. 366 (26), 2443–2454. doi:10.1056/NEJMoa1206690

Van Cutsem, E., Sagar, E., Topal, B., Haustermann, K., and Preen, H. (2016). Gastric cancer. Lancet 388 (10060), 2654–2664. doi:10.1016/S0140-6736(16)30354-3

Vrana, D., Matzenauer, M., Neoral, C., Aujeský, R., Vrba, R., Melichar, B., et al. (2018). From tumour immunology to immunotherapy in gastric and esophageal cancer. Int. J. Mol. Sci. 20 (1), E13. doi:10.3390/ijms2011013

Wang, S., Cowley, L. A., and Liu, X.-S. (2019). Sex differences in cancer immunotherapy efficacy, biomarkers, and therapeutic strategy. Molecules 24 (18), E3214. doi:10.3390/molecules24183214

Wang, S., Zhang, J., He, Z., Wu, K., and Liu, X.-S. (2019). The predictive power of tumor mutational burden in lung cancer immunotherapy response is influenced by patients’ sex. Int. J. Cancer 145 (10), 2840–2849. doi:10.1002/ijc.32327

Wang, Z.-X., Cui, C., Yao, J., Zhang, Y., Li, M., Feng, J., et al. (2022). Toripalimab plus chemotherapy in treatment-naive, advanced esophageal squamous cell carcinoma (JUPITER-06): A multi-center phase 3 trial. Cancer Cell. 40 (3), 277–288.e3. doi:10.1016/j.ccell.2022.02.007

Weadick, C. S., Duffy, A. G., and Kelly, R. J. (2022). Recent advances in immune-based approaches for the treatment of esophagogastric cancer. Expert Opin. Emerg. Drugs 27 (1), 19–31. doi:10.1080/17427849.2021.2007575

Wu, A.-H., Tseng, C.-C., and Bernstein, L. (2003). Hiatal hernia, reflux symptoms, body size, and risk of esophageal and gastric adenocarcinoma. Cancer 98 (5), 940–948. doi:10.1002/cncr.11168

Wu, Y.-Y., Lin, C.-W., Cheng, K.-S., Lin, C., Wang, Y.-M., Lin, I.-T., et al. (2010). Increased programmed death-ligand-1 expression in human gastric epithelial cells in Helicobacter pylori infection. Clin. Exp. Immunol. 161 (3), 551–559. doi:10.1111/j.1365-2189.2010.04217.x

Xu, J., Li, Y., Fan, Q., Shu, Y., Yang, L., Cui, T., et al. (2022). Clinical and biomarker analyses of sintilimab versus chemotherapy as second-line therapy for advanced or metastatic esophageal squamous cell carcinoma: A randomized, open-label phase 2 study (ORIENT-2). Nat. Commun. 13, 837. doi:10.1038/s41467-022-28408-3

Yang, C., Jin, J., Yang, Y., Sun, H., Wu, L., Shen, M., et al. (2022). Androgen receptor-mediated CD8+ T cell stemness programs drive sex differences in antitumor immunity. Immunity 55 (7), 1747. doi:10.1016/j.immuni.2022.07.016

Ye, W., Held, M., Lagergren, J., Engstrand, L., Blot, W. J., McLaughlin, J. K., et al. (2004). Helicobacter pylori infection and gastric atrophy: Risk of adenocarcinoma and squamous-cell carcinoma of the esophagus and adenocarcinoma of the gastric cardia. J. Natl. Cancer Inst. 96 (5), 388–396. doi:10.1093/jnci/djh005

Yi, M., Jiao, D., Xu, H., Liu, Q., Zhao, W., Han, X., et al. (2018). Biomarkers for predicting efficacy of PD-1/PD-L1 inhibitors. Mol. Cancer 17 (1), 129. doi:10.1186/s12943-018-0864-3

Zhu, G.-L., Yang, K.-B., Tang, S.-Q., and Peng, L. (2021). Progression-free survival assessed per immune-related or conventional response criteria, which is the better surrogate endpoint for overall survival in trials of immune-checkpoint inhibitors in lung cancer: A systematic review and meta-analysis. Cancer Med. 10 (23), 8272–8287. doi:10.1002/cam4.4347

Zhu, Y., Li, M., Bo, C., Liu, X., Zhang, J., Li, Z., et al. (2017). Prognostic significance of the lymphocyte-to-monocyte ratio and the tumor-infiltrating lymphocyte to tumor-associated macrophage ratio in patients with stage III/IV esophageal squamous cell carcinoma. Cancer Immunol. Immunother. 66 (3), 343–354. doi:10.1007/s00262-016-1931-5

Zou, K., Yang, S., Zheng, L., Yang, C., and Xiong, B. (2016). Efficacy and safety of target combined chemotherapy in advanced gastric cancer: A meta-analysis and system review. BMC Cancer 16 (1), 737. doi:10.1186/s12885-016-2772-5